Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2024 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
February 08, 2024 01:22 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces Pricing of Upsized Public Offering

SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
February 07, 2024 16:01 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces Proposed Public Offering of Common Stock

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has...
January 05, 2024 09:00 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food...
January 03, 2024 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
December 11, 2023 09:00 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission Validation of novel and fully-human GPRC5D-specific CARs for the development...
December 01, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication...
November 21, 2023 09:00 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present at November and December 2023 Investor Conferences

SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
November 17, 2023 09:00 ET | Source: Sana Biotechnology, Inc

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

Goal is to report UP421 proof of concept data in 2023 and 2024 Potential to remove immunosuppression from islet cell transplantation SEATTLE, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology,...
November 09, 2023 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical...